MetaCap

Aardvark Therapeutics (AARD) vs CervoMed (CRVO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CervoMed (CRVO) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 83.6% versus a loss of 90.2%. CervoMed is the larger company by market cap ($22.1 million vs $20.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-90.15%CRVO-83.56%
+77%-11%-98%
Nov 21, 20251 yearNov 20, 2026
AARD-93.06%CRVO-37.34%
+544%+210%-123%
Feb 10, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus CRVO key metrics
MetricAARDCRVO
Share price$0.9226$1.46
Market cap$20.20M$22.09M
1-day change-7.74%+9.77%
YTD return-92.97%-81.52%
1-year return-90.15%-83.56%
5-year return—-95.01%
EPS (TTM)$-3.33$-2.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$4.01M
Revenue growth (YoY)—-58.86%
Net income (latest FY)$-57.59M$-26.97M
Operating margin—-706.22%
Net margin—-673.06%
52-week high$16.60$10.00
52-week low$0.90$1.27
Distance from 52-week high-94.44%-85.40%
Analyst consensusbuystrong_buy
Avg. price target upside+1104.21%+954.79%
Average volume643.53K489.10K
Shares outstanding21.89M15.13M
Employees2815
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aardvark Therapeutics

AARD stock →

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About CervoMed

CRVO stock →

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

AARD vs CRVO FAQ

Which is bigger, Aardvark Therapeutics or CervoMed?

CervoMed (CRVO) is larger, with a market capitalization of $22.09M compared with $20.20M for Aardvark Therapeutics (AARD).

Which stock has performed better over the past year, AARD or CRVO?

CRVO returned -83.56% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.

Are Aardvark Therapeutics and CervoMed in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons